As third generation estrogen receptor modulator, the selectivity and safety of Bazedoxifene is improved over Tamoxifen whose major adverse effect is increasing the incidence of uterine cancer [33, 56, 57]. This evidence concerns the gene ESR1 and uterine cancer.